OcuSciences Announces Publication Showing Flavoprotein Fluorescence May Detect Improvement in Metabolic Function Preceding Structural Improvement in Patients with Diabetic Macular Edema Treated with Anti-VEGF
ANN ARBOR, Mich.--(BUSINESS WIRE)--OcuSciences, Inc., a clinical-stage biotechnology company developing retinal imagers to detect early disease by assessing retinal metabolic activity, today announced the online publication of its diabetic macular edema study. The findings suggest that FPF can detect improvement in metabolic function that more directly correlates to vision improvement than the improvement in macular thickness measured by optical coherence tomography in DME patients treated with